SCHEMBL1714503

SCHEMBL1714503

O=C1NC(C2CCCCC2)=NC1=Cc1c[nH]c2ncccc12

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CDC7 O00311 9/20 0.50
▸ CHEK1 O14757 1/20 0.48
▸ KMT2A Q03164 1/20 0.46
▸ HASPIN Q8TF76 4/20 0.44
▸ CCNT1 O60563 2/20 0.44
▸ CDK9 P50750 2/20 0.44
▸ OPRL1 P41146 2/20 0.40
▸ OPRM1 P35372 1/20 0.40
▸ OPRK1 P41145 1/20 0.40
▸ DBF4 Q9UBU7 6/20 0.39
▸ CAMKK1 Q8N5S9 1/20 0.39
▸ CAMKK2 Q96RR4 1/20 0.39
▸ ROCK2 O75116 1/20 0.38
▸ CCNB2 O95067 1/20 0.38
▸ MAP4K4 O95819 1/20 0.38
▸ CDK1 P06493 1/20 0.38
▸ RET P07949 1/20 0.38
▸ CCNB1 P14635 1/20 0.38
▸ PRKACA P17612 1/20 0.38
▸ CDK2 P24941 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1714498 1.00 CDC7 (0.50) CDC7CHEK1KMT2AHASPINCCNT1
SCHEMBL13676712 0.94 CHEK1 (0.51) CDC7CHEK1KMT2AHASPINCCNT1
SCHEMBL1713677 0.89 CHEK1 (0.47) CDC7CHEK1KMT2AHASPINCCNT1
SCHEMBL1713681 0.89 CHEK1 (0.47) CDC7CHEK1KMT2AHASPINCCNT1
Hydrochloric Acid SCHEMBL5092905 0.82 CDC7 (0.48) CDC7CHEK1KMT2AHASPINCCNT1
Hydrochloric Acid SCHEMBL5094673 0.82 CDC7 (0.48) CDC7CHEK1KMT2AHASPINCCNT1
Hydrochloric Acid SCHEMBL5094688 0.82 CDC7 (0.48) CDC7CHEK1KMT2AHASPINCCNT1
Hydrochloric Acid SCHEMBL5089787 0.82 CDC7 (0.48) CDC7CHEK1KMT2AHASPINCCNT1
Hydrochloric Acid SCHEMBL5089798 0.82 CDC7 (0.48) CDC7CHEK1KMT2AHASPINCCNT1
Hydrochloric Acid SCHEMBL5092923 0.82 CDC7 (0.48) CDC7CHEK1KMT2AHASPINCCNT1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8314121-B2 Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 SANOFI (FR) 2012-11-20 — — US claimed
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2009-10-08 — — US claimed
US-8314121-B2 Imidazolone derivatives, preparation thereof as drugs, pharmaceutical compositions, and use thereof as protein kinase inhibitors, in particular CDC7 SANOFI (FR) 2012-11-20 — — US disclosed
EP-2094699-B1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI AVENTIS (FR) 2011-07-20 — — EP disclosed
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 SANOFI-AVENTIS (FR) 2009-10-08 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090253679-A1 NEW IMIDAZOLONE DERIVATIVES, PREPARATION THEREOF AS DRUGS, PHARMACEUTICAL COMPOSITIONS, AND USE THEREOF AS PROTEIN KINASE INHIBITORS, IN PARTICULAR CDC7 CDC7, CDK7, CDK17 CDC7 1/4885CHEK1 17/4885KMT2A 3256/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback